2nd Jan 2019 12:33
LONDON (Alliance News) - Renalytix AI PLC said Wednesday that it has exercised an option to secure the exclusive licence for kidney transplant diagnostic technology from the Icahn School of Medicine at Mount Sinai.
Pursuant to the option exercise, the company will secure the licence to a portfolio of diagnostics, referred to as FractalDX, focused on kidney transplant.
The portfolio consists of data, development and intellectual property across different diagnostic indications including identification of post-transplant/sub-clinical acute rejection, prediction of fibrosis/graft survival and pre-transplant/immune stratification.
Renalytix, which develops artificial intelligence enabled clinical diagnostics solutions for kidney disease, said the kidney transplant product portfolio has significant potential to address critical unmet needs in the kidney transplant field, such as transplant donor and recipient status, and determining specific immunosuppression therapy levels for patients in the US and globally.
The company will pay USD1.0 million upfront for the exclusive license and reimbursement of intellectual property legal and other fees of approximately USD300,000 to the Icahn School of Medicine at Mount Sinai.
Shares in Renalytix were untraded at 122.50 pence each on Wednesday.
Related Shares:
Renalytix Plc